Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
22 Mai 2023 - 12:54PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2023
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
Directorate Change
22
May 2023 07:05 BST
Non-Executive Board Appointment
AstraZeneca
PLC announced today that Anna Manz has been appointed as a
Non-Executive Director and a member of the Audit Committee with
effect from 1 September 2023.
Anna
is currently an Executive Director and the Group Chief Financial
Officer of London Stock Exchange Group plc.
Michel
Demaré, Chair of AstraZeneca, said "We are delighted to welcome
Anna to the AstraZeneca Board. She brings extensive cross-sector
business skills and knowledge to the Board, having held
international roles in North America and Asia Pacific and served as
an executive and non-executive in large, listed companies. Anna's
significant financial and strategic leadership experience,
including in areas such as risk, treasury and accounting, will
enable her to fully contribute to the work of our Audit
Committee."
Biographical details - Anna Manz
Anna
joined London Stock Exchange Group plc in November 2020 as Chief
Financial Officer, ahead of the $27 billion acquisition of
Refinitiv. From 2016 - 2020, she was an Executive Director and the
Chief Financial Officer of Johnson Matthey Plc and led its Finance,
Procurement and IT functions. Prior to joining Johnson Matthey,
Anna spent 17 years at Diageo plc in a number of senior finance
roles, including Chief Strategy Officer and as a member of the
Executive Committee. She brings extensive expertise in accounting,
corporate finance and mergers and acquisitions, as well as
experience of business diversification and
transformation.
Anna
has been a Non-Executive Director of ITV plc since 2016 and has
served on its Audit Committee and Remuneration Committee for most
of that period. She will step down as a Non-Executive Director of
ITV at the end of August this year.
Except
as set out above, no disclosure obligations arise under paragraphs
(1) to (6) of LR 9.6.13 R of the UK Financial Conduct Authority's
Listing Rules in respect of this appointment.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
22 May 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Aug 2023 bis Sep 2023
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Sep 2022 bis Sep 2023
